
The two biggest rival US pharma firms have joined forces to help develop a new combination treatment for certain non-small …

Advaxis and Merck have signed a research deal to investigational Merck’s PD-1 inhibitor pembrolizumab in combination with Advaxis’ listeria-based cancer …

Merck’s oncology drug pembrolizumab has taken a big step towards becoming Europe’s first PD-1 cancer treatment as the EMA accepts …

